Article
Medicine, Research & Experimental
Minwei He, Xing Wang, Wei Chen, Jianzhi Zhang, Ying Xiong, Lulu Cao, Liyi Zhang, Ning Zhao, Yue Yang, Lu Wang
Summary: PTPIP51 is downregulated in non-small cell lung cancer (NSCLC), but its overexpression inhibits EGFR signaling pathway and promotes apoptosis, acting as a tumor suppressor in NSCLC.
Review
Medicine, Research & Experimental
Santoshi Naik, Ajjappla Basavaraj Shreya, Ruchira Raychaudhuri, Abhijeet Pandey, Shaila A. Lewis, Manali Hazarika, Sulatha Bhandary, Bola Sadashiva Satish Rao, Srinivas Mutalik
Summary: This article discusses the current research on using siRNA-based gene silencing strategies to treat glaucoma, including discussions on ocular structures, administration routes, viral and non-viral vectors, as well as basic strategies and challenges in siRNA therapy. Different therapeutic targets for glaucoma, current siRNA-based drugs used in treatment, and strategies for siRNA-based treatment after glaucoma surgery are also briefly mentioned.
Article
Chemistry, Multidisciplinary
Huimin Xu, Jianqiao Chang, Hao Wu, Haoyu Wang, Wenjing Xie, Yunchao Li, Xiaohong Li, Yang Zhang, Louzhen Fan
Summary: siRNA-based gene therapy is a promising strategy for tumor treatment. Novel gene vectors, such as LAAM GUA-CDs, which can target tumor cells and deliver siRNA without causing side effects, have been designed and synthesized. LAAM GUA-CDs loaded with siBcl-2 exhibit a high tumor inhibition rate, twice as effective as commercial Lipofectamine 2000. LAAM GUA-CDs provide a versatile approach for tumor-targeted siRNA delivery and cancer therapy.
Article
Chemistry, Multidisciplinary
Jieun Lee, Wooic Son, Juhyeong Hong, Yoonsung Song, Chul-Su Yang, Yong-Hee Kim
Summary: Sepsis is a systemic inflammatory response syndrome caused by bacterial infection. Current sepsis therapy involving antibiotics has limitations such as side effects and high costs. Therefore, there is a growing need for sepsis treatment free from side effects.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Biochemistry & Molecular Biology
Asal Jalal Abadi, Ali Zarrabi, Mohammad Hossein Gholami, Sepideh Mirzaei, Farid Hashemi, Amirhossein Zabolian, Maliheh Entezari, Kiavash Hushmandi, Milad Ashrafizadeh, Haroon Khan, Alan Prem Kumar
Summary: miRNAs play vital roles in breast and lung cancer by regulating the PTEN signaling pathway. The dysregulation of miRNAs in breast and lung cancers is associated with the malignant behavior of tumors.
Article
Biochemistry & Molecular Biology
Jian-Hua Luo, Silvia Liu, Junyan Tao, Bao-Guo Ren, Katherine Luo, Zhang-Hui Chen, Michael Nalesnik, Kathleen Cieply, Tianzhou Ma, Shi-Yuan Cheng, Qi Chen, George K. Michalopoulos, Joel B. Nelson, Rohit Bhargava, Jun Zhang, Deqin Ma, David Jarrard, Arjun Pennathur, James D. Luketich, Donald B. DeFranco, Satdarshan Paul Monga, George Tseng, Yan-Ping Yu
Summary: The fusion gene Pten-NOLC1, derived from Pten gene, is a driver for human cancers as it promotes cancer proliferation, growth, invasion, and metastasis. Its presence in primary cancer samples and cancer cell lines from different organs suggests its significance in oncogenesis.
Review
Biochemistry & Molecular Biology
Noelle D. Germain, Wendy K. Chung, Patrick D. Sarmiere
Summary: Advances in genome sequencing have facilitated the identification of genomic variants underlying rare neurodevelopmental and neurodegenerative disorders. RNA interference (RNAi) technologies, such as siRNA, miRNA, and shRNA, are being developed as potential therapeutic approaches for neurological diseases. This article provides a brief review of the mechanism of action of RNAi approaches, discusses the advantages, challenges, and considerations related to developing RNAi therapeutics for neurological diseases, and highlights promising examples.
MOLECULAR ASPECTS OF MEDICINE
(2023)
Retraction
Cell Biology
Ye Zhang, Rui Sui, Yi Chen, Hanyang Liang, Ji Shi, Haozhe Piao
Summary: The retraction of the article was based on an investigation following allegations raised by a third party, which found flaws and inconsistencies between the results presented and the experimental methods described, leading the editors to consider the conclusions of the article to be invalid.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Review
Instruments & Instrumentation
Indra Rautela, Aditi Sharma, Pallavi Dheer, Priya Thapliyal, Shweta Sahni, Vimlendu Bhushan Sinha, Manish Dev Sharma
Summary: RNA interference has led to the development of siRNA-based therapeutics for gene therapy purposes, particularly in treating cancer. Despite the challenges associated with siRNA delivery systems, advancements have been made in targeted delivery methods using different types of materials.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2022)
Article
Chemistry, Multidisciplinary
Jong Won Lee, Jiwon Choi, Yeonho Choi, Kwangmeyung Kim, Yoosoo Yang, Sun Hwa Kim, Hong Yeol Yoon, Ick Chan Kwon
Summary: RNA interference (RNAi) is a cellular mechanism that regulates gene expression, with small interfering RNA molecules (siRNA) mediating mRNA degradation. Despite the promising therapeutic potential of RNAi technology for diseases like cancer, challenges such as biological instability and limited delivery efficiency remain. Recent advancements in siRNA delivery strategies using cationic lipids and polymers have shown improved pharmacokinetics and delivery efficiency.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Medicine, General & Internal
Moqbel Ali Moqbel Redhwan, M. G. Hariprasad, Suman Samaddar, Sumaia Abdulbari Ahmed Ali Hard, Vidyabhushan Yadav, Apurbo Mukherjee, Rahul Kumar
Summary: This review examines the clinical trials on siRNA published in the last 5 years to understand its benefits, pharmacokinetics, and safety. So far, 55 clinical studies have been conducted on siRNA, showing its effectiveness and safety in treating various diseases. However, there are limitations and uncertainties, such as cellular uptake, precise targeting, and elimination from the body.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Oncology
Junlin Xie, Shubin Wang
Summary: siRNA therapy has the potential to be one of the most effective methods for treating colorectal cancer liver metastasis (CRLM) by targeting major metastasis-related signaling pathways. However, the therapy faces challenges such as poor serum stability and nonspecific uptake, which require the development of delivery systems.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2022)
Review
Pharmacology & Pharmacy
Priyanga Ranasinghe, Melisande L. Addison, James W. Dear, David J. Webb
Summary: Post-transcriptional gene silencing can be achieved through siRNA therapy, which uses synthetic short double-stranded RNA molecules to specifically target and degrade mRNA transcripts. This technology offers advantages such as broad targeting capabilities and long-lasting effects. However, challenges in terms of pharmacokinetics and pharmacodynamics have been addressed through chemical modification and delivery systems. Several siRNA therapies have been approved for clinical use, but further advancements are needed to target organs beyond the liver and reach special sites.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ming-Jen Lee, Inyoul Lee, Kai Wang
Summary: The development of new sequencing technologies in the post-genomic era has accelerated the identification of causative mutations of several single gene disorders. Advances in cell and animal models provide insights into the underlying pathogenesis, which facilitates the development and maturation of new treatment strategies. The progress in biochemistry and molecular biology has established a new class of therapeutics-the short RNAs and expressible long RNAs. The sequences of therapeutic RNAs can be optimized to enhance their stability and translatability with reduced immunogenicity.
Article
Biotechnology & Applied Microbiology
Donna Klein, Shalom Goldberg, Christopher S. Theile, Richard Dambra, Kathleen Haskell, Elise Kuhar, Tricia Lin, Rubina Parmar, Muthiah Manoharan, Mark Richter, Meizhen Wu, Jeannine Mendrola Zarazowski, Vasant Jadhav, Martin A. Maier, Laura Sepp-Lorenzino, Karyn O'Neil, Vadim Dudkin
Summary: The combination of Centyrins and siRNAs in this study has successfully achieved posttranscriptional gene silencing in tumor cells, allowing for targeted therapy of cancer cells and oncogene silencing.
Article
Biotechnology & Applied Microbiology
Xintong Ge, Mengtian Guo, Tianpeng Hu, Wenzhu Li, Shan Huang, Zhenyu Yin, Ying Li, Fanglian Chen, Luoyun Zhu, Chunsheng Kang, Rongcai Jiang, Ping Lei, Jianning Zhang
Article
Cell Biology
Xingliang Dai, Yunfei Wang, Xuchen Dong, Minfeng Sheng, Haiyang Wang, Jia Shi, Yujing Sheng, Liang Liu, Qianqian Jiang, Yanming Chen, Bingshan Wu, Xuejun Yang, Hongwei Cheng, Chunsheng Kang, Jun Dong
Review
Immunology
Na Zhang, Li Wei, Meng Ye, Chunsheng Kang, Hua You
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Ying Cai, Eryan Yang, Xiuhua Yao, Xuebin Zhang, Qixue Wang, Yunfei Wang, Ji Liu, Weijia Fan, Kaikai Yi, Chunsheng Kang, Jialing Wu
Summary: tPA exerts neuroprotective effects by increasing phosphorylation of AMPK and expression of FUNDC1, thereby inhibiting apoptosis and improving mitochondrial function.
Review
Oncology
Luyue Chen, Kai Huang, Kaikai Yi, Yanlin Huang, Xinhua Tian, Chunsheng Kang
Review
Oncology
Tao Jiang, Do-Hyun Nam, Zvi Ram, Wai-Sang Poon, Jiguang Wang, Damdindorj Boldbaatar, Ying Mao, Wenbin Ma, Qing Mao, Yongping You, Chuanlu Jiang, Xuejun Yang, Chunsheng Kang, Xiaoguang Qiu, Wenbin Li, Shaowu Li, Ling Chen, Xuejun Li, Zhixiong Liu, Weimin Wang, Hongmin Bai, Yu Yao, Shouwei Li, Anhua Wu, Ke Sai, Guilin Li, Kun Yao, Xinting Wei, Xianzhi Liu, Zhiwen Zhang, Yiwu Dai, Shengqing Lv, Liang Wang, Zhixiong Lin, Jun Dong, Guozheng Xu, Xiaodong Ma, Wei Zhang, Chuanbao Zhang, Baoshi Chen, Gan You, Yongzhi Wang, Yinyan Wang, Zhaoshi Bao, Pei Yang, Xing Fan, Xing Liu, Zheng Zhao, Zheng Wang, Yiming Li, Zhiliang Wang, Guanzhang Li, Shengyu Fang, Lianwang Li, Yanwei Liu, Shuai Liu, Xia Shan, Yuqing Liu, Ruichao Chai, Huimin Hu, Jing Chen, Wei Yan, Jinquan Cai, Hongjun Wang, Lingchao Chen, Yuan Yang, Yu Wang, Lei Han, Qixue Wang
Summary: The joint guideline committee of Chinese Glioma Cooperative Group, Society for Neuro-Oncology of China, and Chinese Brain Cancer Association has updated the clinical practice guideline to provide recommendations for the diagnosis and management of diffuse gliomas. The guidelines focus on molecular and pathological diagnostics, as well as main treatment modalities including surgery, radiotherapy, and chemotherapy. Additionally, the guidelines integrate results from clinical trials of immune therapies and target therapies as future directions.
Article
Oncology
Jixing Zhao, Shixue Yang, Xiaoteng Cui, Qixue Wang, Eryan Yang, Fei Tong, Biao Hong, Menglin Xiao, Lei Xin, Can Xu, Yanli Tan, Chunsheng Kang
Summary: Researchers have discovered a small-molecule inhibitor called EPIC-0412 that enhances the effectiveness of the chemotherapy drug TMZ in treating GBM. By disrupting DNA damage repair pathways and targeting MGMT, EPIC-0412 sensitizes GBM cells to TMZ and induces cell cycle arrest and apoptosis. The study also shows that EPIC-0412 epigenetically silences MGMT through specific pathways.
Editorial Material
Oncology
Xing Liu, Chunsheng Kang
Article
Oncology
Lei Xin, Yanli Tan, Yuanxue Zhu, Xiaoteng Cui, Qixue Wang, Jixing Zhao, Shaohui Tian, Can Xu, Menglin Xiao, Biao Hong, Jianglong Xu, Xiaoye Yuan, Changsheng Wang, Chunsheng Kang, Chuan Fang
Summary: This study identified a potential small-molecule inhibitor, EPIC-0307, that selectively disrupted the PRADX-EZH2 interaction to upregulate expressions of tumor suppressor genes, thereby exerting its antitumor effects on GBM cells. EPIC-0307 treatment also increased the chemotherapeutic efficacy of TMZ by epigenetically downregulating DNA repair-associated genes and MGMT expression in GBM cells.
Review
Oncology
Xiaoteng Cui, Yunfei Wang, Junhu Zhou, Qixue Wang, Chunsheng Kang
Summary: Malignant gliomas are difficult to diagnose and treat due to their infiltrative growth pattern, rapid progression, and poor prognosis. Temozolomide (TMZ) is the only first-line chemotherapeutic drug for malignant gliomas that can cross the blood-brain barrier, but some patients are insensitive to TMZ and can develop acquired resistance during treatment.
CANCER BIOLOGY & MEDICINE
(2023)
Article
Oncology
Kaikai Yi, Qi Zhan, Qixue Wang, Yanli Tan, Chuan Fang, Yunfei Wang, Junhu Zhou, Chao Yang, Yansheng Li, Chunsheng Kang
Summary: This study revealed that PTRF promotes GBM tumor proliferation and suppresses immune responses through a lipid remodeling pathway involving cPLA2. The overexpression of PTRF alters the metabolism of cells, affecting the growth and immune infiltration of GBM tumors. These findings highlight new therapeutic targets for GBM treatment.
Article
Engineering, Multidisciplinary
Long LiXia, Cheng LinJie, Hou JingJing, Wang LiMei, Wang Xu, He LiGang, Li SiDi, Zhao Jin, Hou Xin, Kang ChunSheng, Yuan XuBo
Summary: Increasing the branching degree of star-branched copolymers can improve the blood circulation and tumor-targeting effects of polymeric nanovehicles in vivo, allowing the payload to persist longer in the bloodstream.
SCIENCE CHINA-TECHNOLOGICAL SCIENCES
(2021)
Article
Medicine, Research & Experimental
Lin Wang, Junhu Zhou, Qixue Wang, Yunfei Wang, Chunsheng Kang
Summary: This study proposes a potential anti-SARS-CoV-2 strategy based on the CRISPR-Cas13a system, identifying a specific RNA segment of the spike protein and designing an efficient crRNA sequence for cleavage. It provides a rapid design pipeline for an antiviral tool against SARS-CoV-2 and introduces a novel approach for anti-virus study.
Article
Nanoscience & Nanotechnology
Yadan Zheng, Zhanzhan Zhang, Qi Liu, Yu Zhao, Chunxiong Zheng, Jialei Hao, Kaikai Yi, Ying Wang, Chun Wang, Xinzhi Zhao, Linqi Shi, Chunsheng Kang, Yang Liu
ACS APPLIED BIO MATERIALS
(2020)
Article
Medicine, Research & Experimental
Yansheng Li, Xing Liu, Xiaoteng Cui, Yanli Tan, Qixue Wang, Yunfei Wang, Can Xu, Chuan Fang, Chunsheng Kang
Summary: The study identified a novel cancer driver lncRNA named PRADX in glioblastoma and colon adenocarcinoma, which is highly expressed in tumor cells and tissues. Through various experiments, PRADX was found to interact with EZH2 protein, increase H3K27 trimethylation in the UBXN1 gene promoter, and promote NF-KB activity by suppressing UBXN1. Knockdown of PRADX inhibited tumor cell viability and growth both in vitro and in vivo, suggesting its potential as a therapeutic target for these cancers.